Reading the tape
NASDAQ: NCEL
NewcelX Ltd.
Healthcare · Biotechnology
Market Cap
$1.98M
52w High
$30.80
52w Low
$1.83
P/E
-0.82
Volume
179.47K
Outstanding Shares
450.00K
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -70%FCF (TTM): -214.12%
What changed
The stock fell 70% over the last year. Free cash flow declined 214.12% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 214.12% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.
CEORonen Twito
SectorHealthcare
IndustryBiotechnology
Employees11
IPO dateOct 24, 2025
Valuation
Forward P/E—
EV/EBITDA0.02
Enterprise value-$76.57K
Stock splits
Oct 31, 2025↓ Reverse
Every 10 shares became 1
Sep 27, 2024↓ Reverse
Every 40 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-140.85%▼202.22%vs FY2023
Analyst consensus
RatingBuy
Target price—
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 15, 2026
Q1 FY26 · EPS est — · Revenue est —
View